ArticleJournal of medical biochemistry2025
Serum thioredoxin and lactoferrin in rheumatoid arthritis and their association with rheumatoid factor.
Article in Journal of medical biochemistry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Analysis of inflammatory immune correlation of the coagulation spectrum, PT, FBG, FDP, D-D in autoimmune diseases.Journal of medical biochemistry · 2026Article
- Review
- Lactoferrin and Thioredoxin in Rheumatoid Arthritis Are Associated with Fibrinogen but Not with Other Acute Phase Proteins.International journal of molecular sciences · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Thioredoxin (Trx) and lactoferrin (Lf) are multifunctional proteins that are part of the body's antioxidant defence and counteract oxidative tissue damage. Our study aims to investigate Trx and LF levels in the serum of rheumatoid arthritis (RA) patients and establish the association of these proteins with the rheumatoid factor (RF) and other disease markers. Methods: The study included 114 patients with RA and 42 healthy subjects. Serum concentrations of Trx 1, LF, RF, anti-cyclic citrullinated peptide (anti-CCP) antibodies, Creactive protein (CRP), and IL-6 were determined using commercially available ELISA kits. Results: Serum thioredoxin 1 levels in RA were significantly higher compared to the control group, 36.4 (29.6-40.2), ng/mL versus 19.0 (16.3-26.8), ng/mL, p<0.0001. Serum lactoferrin levels were elevated in RA compared to the control group. However, the difference was not statistically significant, 579.6 (312.8-947.5) ng/mL versus 519.0 (262.5-928.0) ng/mL. We found substantial negative Trx 1 and LF correlations with rheumatoid factor in RA (r=-0.254, p=0.05 and r=-0.238, p=0.014, respectively). The correlations of thioredoxin and lactoferrin with other disease markers, such as anti-CCP antibodies, DAS28, erythrocyte sedimentation rate (ESR), CRP, and IL6 were not statistically significant. A strong positive correlation between Trx 1 and LF was observed in the study group of RA patients (r=0.519, p<0.0001) but not in the control group. Conclusions: Thioredoxin and lactoferrin were associated with rheumatoid factor but not with anti-CCP antibodies and systemic disease activity; therefore, the two proteins may serve as new biomarkers for assessing pathological changes and monitoring disease severity and progression in RA.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.